Abstract
This article describes the discovery and development of the first highly selective, small molecule antagonist of the muscarinic acetylcholine receptor subtype I (mAChR1 or M1). An M1 functional, cell-based, calcium-mobilization assay identified three distinct chemical series with initial selectivity for M1 versus M4. An iterative parallel synthesis approach was employed to optimize all three series in parallel, which led to the development of novel microwave-assisted chemistry and provided important take home lessons for probe development projects. Ultimately, this effort produced VU0255035, a potent (IC50 = 130 nM) and selective ( > 75-fold vs. M2-M5 and > 10 iM vs. a panel of 75 GPCRs, ion channels and transporters) small molecule M1 antagonist. Further profiling demonstrated that VU0255035 was centrally penetrant (BrainAUC/PlasmaAUC of 0.48) and active in vivo, rendering it acceptable as both an in vitro and in vivo MLSCN/ MLPCN probe molecule for studying and dissecting M1 function.
Keywords: Muscarinic, acetylcholine, mAChR, M1, antagonist
Current Topics in Medicinal Chemistry
Title: Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe
Volume: 9 Issue: 13
Author(s): Satyawan Jadhav, Craig W. Lindsley, P. Jeffrey Conn, Fang Zheng, Matthew M. Mock, Colleen M. Niswender, Joy Marlo, Carrie K. Jones, Leslie A. Aldrich, C. David Weaver, Matthew M. Mulder, J. Phillip Kennedy, Natalia T. Nalywajko, Richard Williams, Thomas M. Bridges, L. Michelle Lewis and Douglas J. Sheffler
Affiliation:
Keywords: Muscarinic, acetylcholine, mAChR, M1, antagonist
Abstract: This article describes the discovery and development of the first highly selective, small molecule antagonist of the muscarinic acetylcholine receptor subtype I (mAChR1 or M1). An M1 functional, cell-based, calcium-mobilization assay identified three distinct chemical series with initial selectivity for M1 versus M4. An iterative parallel synthesis approach was employed to optimize all three series in parallel, which led to the development of novel microwave-assisted chemistry and provided important take home lessons for probe development projects. Ultimately, this effort produced VU0255035, a potent (IC50 = 130 nM) and selective ( > 75-fold vs. M2-M5 and > 10 iM vs. a panel of 75 GPCRs, ion channels and transporters) small molecule M1 antagonist. Further profiling demonstrated that VU0255035 was centrally penetrant (BrainAUC/PlasmaAUC of 0.48) and active in vivo, rendering it acceptable as both an in vitro and in vivo MLSCN/ MLPCN probe molecule for studying and dissecting M1 function.
Export Options
About this article
Cite this article as:
Jadhav Satyawan, Lindsley W. Craig, Conn Jeffrey P., Zheng Fang, Mock M. Matthew, Niswender M. Colleen, Marlo Joy, Jones K. Carrie, Aldrich A. Leslie, Weaver David C., Mulder M. Matthew, Kennedy Phillip J., Nalywajko T. Natalia, Williams Richard, Bridges M. Thomas, Lewis Michelle L. and Sheffler J. Douglas, Discovery and Development of a Potent and Highly Selective Small Molecule Muscarinic Acetylcholine Receptor Subtype I (mAChR 1 or M1) Antagonist In Vitro and In Vivo Probe, Current Topics in Medicinal Chemistry 2009; 9 (13) . https://dx.doi.org/10.2174/156802609789753635
DOI https://dx.doi.org/10.2174/156802609789753635 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of the Combination of Microwave and Parallel Synthesis in Medicinal Chemistry
Combinatorial Chemistry & High Throughput Screening Glycine Transporter-1: A New Potential Therapeutic Target for Schizophrenia
Current Pharmaceutical Design Protein Tyrosine Phosphatase 1B Inhibition: Opportunities and Challenges
Current Medicinal Chemistry Recent Advances in Semisynthesis, Biosynthesis, Biological Activities,Mode of Action, and Structure-Activity Relationship of Podophyllotoxins:An Update (2008-2010)
Mini-Reviews in Medicinal Chemistry N-Acylamidophosphinates: Structure, Properties and Complexation Towards Main Group Metal Cations
Current Organic Chemistry Current Understanding of Cardiac Troponins Metabolism: A Narrative Review
Current Medicinal Chemistry Fyn Kinase in Brain Diseases and Cancer: The Search for Inhibitors
Current Medicinal Chemistry Synthesis of trans-fused Octahydroisoindole-1-carboxylic Acids
Letters in Organic Chemistry Structural Diversity of Neuritogenic Substances and their Application Perspective
Mini-Reviews in Medicinal Chemistry High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists
Current Topics in Medicinal Chemistry Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Thymoquinone: A Review on its Pharmacological Importance, and its Association with Oxidative Stress, COVID-19, and Radiotherapy
Mini-Reviews in Medicinal Chemistry The CRF1 Receptor, a Novel Target for the Treatment of Depression, Anxiety, and Stress-Related Disorders
CNS & Neurological Disorders - Drug Targets Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design Biomarkers and Multiple Drug Resistance in Breast Cancer
Current Cancer Drug Targets Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario
Current Pharmaceutical Design Predicting the Cumulative Number of Cases of the COVID-19 Epidemic in India from Early Data
The Natural Products Journal Synthesis, Antimicrobial and Pharmacological Evaluation of Thioureaderivatives of 4H-1,2,4-triazole
Letters in Drug Design & Discovery HIV-1 Fitness and Disease Progression: Insights from the SIV-Macaque Model
Current HIV Research